Home Guidelines & Resources Clinical Trials Registry

Clinical Trials Registry

Our Clinical Trials Registry is a free service to connect physicians to clinical trials in respiratory disease. Clinical trials power medical progress, allowing researchers to test new ways to prevent, detect, and treat respiratory disease. Without clinical trials, treatment advancements would be significantly hampered.

Ongoing groundbreaking research could have a measurable impact on patient care, but a lack of clinical trial participants is significantly slowing research and threatening the development of new treatments. Recruiting and retaining trial participants are the greatest challenges to developing the next generation of treatment options.

Participation in clinical trials provides an opportunity to advance and accelerate medical research and contribute to an improved health outlook for future generations. Use our registry to get information on how you can be involved in a clinical trial.

Idiopathic pulmonary fibrosis (IPF) clinical trial

For patients with IPF who may or may not already be taking either pirfenidone or nintedanib, Genentech is running a global multicenter phase 3 clinical trial to evaluate the safety and effectiveness of recombinant human pentraxin-2 (rhPTX-2; also known as PRM-151). This phase 3 trial is being initiated based upon the results from the phase 2 trial of rhPTX-2 which demonstrated statistically significant and clinically meaningful outcomes in patients with IPF (Raghu et al, JAMA. 2018;319(22):2299-2307)

A number of clinical trial sites are anticipated to be set up across the United States. For additional information, please contact Genentech at: 888-662-6728, or visit

CENTERSTONE - Influenza Household Transmission Clinical Trial

A study to assess the efficacy of a single oral dose of baloxavir marboxil versus placebo to reduce the direct transmission of influenza A or B in households is taking place at multiple sites around the United States and other countries. It is open to otherwise-healthy participants between the ages of 5 and 64 with confirmed influenza infection, who have had influenza symptoms for no more than 48 hours. Participants must also have at least 2 household members who are confirmed influenza-negative and are willing to participate.

For more information or to locate a site near you, please visit

Do your moderate to severe allergic asthma patients have difficulty exercising or sleeping?

Genentech is doing an open label study investigating the impact of omalizumab on exercise capacity, physical activity and sleep. If you treat moderate to severe allergic asthma patients over 18 who would like to participate or if you would like to learn more about the clinical study, contact Genentech at: 888-662-6728, visit


The American College of Chest Physicians (CHEST), in furtherance of its mission of advancing research, has established this page to provide a list of clinical trials seeking individuals to serve as principal investigators or to otherwise participate. CHEST has neither conducted an independent investigation of the nature, quality, scientific merit, or subject matter of the clinical trials, nor has it established criteria or preconditions for those trials being listed on this page. CHEST, its officers, regents, members, and employees are not recommending or endorsing the listed trials or the companies sponsoring trials and specifically disclaims liability for damages of any kind arising out of a member, health-care provider, or any other individual’s participation in a listed trial.